YK BIOVENTURES
YK BIOVENTURES is a Seed, Series A, Series B and Series C+ fund in the US and South Korea writing $1M–$10M checks into biotechnology, drug-discovery, life-sciences, pharmaceuticals and healthcare-tech.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- biotechnology, drug-discovery, life-sciences, pharmaceuticals, healthcare-tech
- Check size
- $1M–$10M
- Invests in
- US-wide, South Korea
- Actively investing
- Yes
- Founded
- 2023
- Assets under management
- 100000000
Thesis
YK BioVentures is a venture capital firm established in 2023, focusing on the healthcare and biotechnology sectors. Their investment thesis centers on companies developing novel technologies and therapeutic solutions to address unmet medical needs. The firm's strategy includes providing capital and strategic guidance, leveraging deep industry expertise to support scientific breakthroughs from research to clinical application. Key areas of interest include biotechnology, drug discovery, life sciences, and pharmaceuticals. While primarily U.S.-based, they also show a geographical preference for investments in South Korea. YK BioVentures invests across multiple stages, including Seed/Angel, Early Stage, and Late Stage VC, with a specific focus on Series A rounds. The typical check size ranges from $1 million to $10 million. The firm plans to raise a $100 million fund. They position themselves as "Beyond Capital," emphasizing industry experience and connections alongside financial investment to accelerate transformative medical advancements and improve global health outcomes.
Common questions
Does YK BIOVENTURES invest at the Seed stage?
Yes. YK BIOVENTURES lists Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does YK BIOVENTURES write?
YK BIOVENTURES writes $1M–$10M checks.
Where does YK BIOVENTURES invest?
YK BIOVENTURES invests in the US and South Korea.